CN116615438A - 用于治疗或预防心肌损伤的肽 - Google Patents

用于治疗或预防心肌损伤的肽 Download PDF

Info

Publication number
CN116615438A
CN116615438A CN202180051469.6A CN202180051469A CN116615438A CN 116615438 A CN116615438 A CN 116615438A CN 202180051469 A CN202180051469 A CN 202180051469A CN 116615438 A CN116615438 A CN 116615438A
Authority
CN
China
Prior art keywords
peptide
subject
aid
tat
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180051469.6A
Other languages
English (en)
Chinese (zh)
Inventor
L·胡尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Western Australia
Original Assignee
University of Western Australia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020902986A external-priority patent/AU2020902986A0/en
Application filed by University of Western Australia filed Critical University of Western Australia
Publication of CN116615438A publication Critical patent/CN116615438A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
CN202180051469.6A 2020-08-21 2021-08-20 用于治疗或预防心肌损伤的肽 Pending CN116615438A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2020902986A AU2020902986A0 (en) 2020-08-21 Peptides for Use in the Treatment or Prevention of Myocardial Damage
AU2020902986 2020-08-21
PCT/AU2021/050928 WO2022036411A1 (en) 2020-08-21 2021-08-20 Peptides for use in the treatment or prevention of myocardial damage

Publications (1)

Publication Number Publication Date
CN116615438A true CN116615438A (zh) 2023-08-18

Family

ID=80322294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180051469.6A Pending CN116615438A (zh) 2020-08-21 2021-08-20 用于治疗或预防心肌损伤的肽

Country Status (8)

Country Link
US (1) US20240158447A1 (https=)
EP (1) EP4200314A4 (https=)
JP (1) JP7776492B2 (https=)
KR (1) KR20230054440A (https=)
CN (1) CN116615438A (https=)
AU (1) AU2021327085A1 (https=)
CA (1) CA3189838A1 (https=)
WO (1) WO2022036411A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491523B2 (en) * 2004-05-11 2009-02-17 Hirsch Joel A Voltage-dependent calcium channel beta subunit functional core
EP2173372B1 (en) * 2007-06-18 2014-11-19 Agency for Science, Technology and Research Novel peptides and protein and uses thereof
WO2013113060A1 (en) * 2012-01-31 2013-08-08 The University Of Western Australia Peptide
US11474098B2 (en) * 2017-12-22 2022-10-18 The Trustees Of Columbia University In The City Of New York Drug target for preventing pathologic calcium overload in cardiomyocytes and methods of screening for same

Also Published As

Publication number Publication date
KR20230054440A (ko) 2023-04-24
WO2022036411A9 (en) 2025-10-02
AU2021327085A1 (en) 2023-03-02
JP2023537934A (ja) 2023-09-06
EP4200314A4 (en) 2025-01-01
CA3189838A1 (en) 2022-02-24
JP7776492B2 (ja) 2025-11-26
EP4200314A1 (en) 2023-06-28
US20240158447A1 (en) 2024-05-16
WO2022036411A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
US11141469B2 (en) Methods and compositions for treating aging-associated conditions
EP1417228B1 (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
KR102434879B1 (ko) 폐혈관 질환 치료용 조성물 및 방법
JP6046493B2 (ja) プロミニン−１の血管新生促進フラグメントおよびその使用
KR20190019171A (ko) 섬유증 치료에서 사용하기 위한 wnt 억제제
JPWO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
JP7697879B2 (ja) 筋肉減少症又は廃用性萎縮症の治療のための組成物
JP2010239971A (ja) 細胞におけるペルオキシソームカタラーゼ機能の促進
JP2009521470A (ja) シヌクレイン障害の治療
JP2020536065A (ja) 興奮性神経毒性に関連した損傷の治療用ペプチド組成物
JP2024504467A (ja) がん療法で使用するための乳酸脱水素酵素活性のポリペプチド阻害剤
CN116615438A (zh) 用于治疗或预防心肌损伤的肽
JP7825238B2 (ja) アミロイドペプチドバリアント
WO2013113060A1 (en) Peptide
US20080075713A1 (en) Protein Disulfide Isomerase and ABC Transporter Homologous Proteins Involved in the Regulation of Energy Homeostasis
JP2006515168A5 (https=)
CN110914286B (zh) 自噬抑制剂
WO2006075172A2 (en) Methods for identifying compounds capable of modulating cftr/ck2 interaction and/or cftr phosphorylation by ck2
JP2001255318A (ja) 神経細胞死抑制作用を有する薬剤及びそのスクリーニング方法
JP2024528351A (ja) ポリペプチド抑制剤及びその用途
FR2853911A1 (fr) Gene induit par l'insuline, comme cible therapeutique dans le diabete
US20040063161A1 (en) Compositions and method of treating Alzheimer's disease
HK1247102B (zh) 用於治疗衰老相关病症的方法和组合物
BR112015020143B1 (pt) Composição tópica farmacêutica no tratamento ocular tópico e/ou na prevenção de doenças neurodegenerativas da retina

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination